Hormonal Hormone replacement therapyFDA-approved medicinePrescription drug

Estradiol Transdermal Patch

Estrogen Patch · Estradiol Patch · Vivelle-Dot

Evidence: Approved label. Example dose: finalize with a provider. Not a fact-check stamp.

0.0375 mg/day patch (mid-low starting dose) – 0.05-0.1 mg/day Topical Twice weekly (change every 3-4 days)

Steroid hormoneEstrogen

Estradiol transdermal patches deliver 17-beta-estradiol through the skin at a controlled rate, bypassing hepatic first-pass metabolism. This route produces steadier serum levels than oral estradiol and avoids the spike in clotting factors seen with oral estrogen. Twice-weekly cadence (every 3-4 days) is standard for most matrix-type patches (Vivelle-Dot, Minivelle, generic estradiol). Strengths from 0.025 mg/day to 0.1 mg/day cover the typical menopausal hormone therapy range. In women with an intact uterus, estradiol MUST be combined with a progestogen to oppose endometrial proliferation.

Quick Start

Route

Transdermal Patch

Start low

0.0375 mg/day Topical

Frequency

Twice weekly (change every 3-4 days)

Timing

Anytime

Starting dose. 0.0375 mg/day — Patch (mid-low starting dose)

Apply to clean dry skin on lower abdomen or buttocks. Rotate sites.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

0.0375 mg/day patch (mid-low starting dose) · Transdermal Patch · Twice weekly (change every 3-4 days)

conservative starter

0.0375 mg/day patch (mid-low starting dose)

Twice weekly (change every 3-4 days)

Standard

Female Hormone Replacement

0.05-0.1 mg/day · Topical · Weekly

human clinical trial · FDA Climara label

Apply to a clean, dry, hairless area of the lower abdomen or buttocks. Rotate sites weekly.

0.05-0.1 mg/day

Weekly

◆

How it works

17-beta-estradiol binds intracellular estrogen receptors (ER-alpha and ER-beta) in target tissues. Receptor-ligand complexes translocate to the nucleus and act as transcription factors at estrogen response elements (EREs), modulating expression of hundreds of genes. Transdermal delivery avoids first-pass hepatic metabolism, producing roughly 3x higher bioavailability than oral estradiol and minimizing hepatic synthesis of clotting factors, SHBG, and triglycerides. Steady-state serum estradiol of 40-100 pg/mL is typical on mid-range patches.

What to expect

Early

Days 1–7

1-2 weeks: vasomotor symptom reduction begins

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

A 0.0375 mg/day estradiol matrix patch changed twice weekly exactly matches quick start.

In this multicenter, randomized, placebo-controlled, parallel-group study, 261 surgically or naturally postmenopausal women were randomized to apply the estradiol matrix transdermal system (0.025, 0.0375, 0.05, or 0.1 mg/d) or matching placebo twice a week for 2 years.

An estradiol matrix transdermal system for the prevention of postmenopausal bone loss. Clinical therapeutics · 2000 · PMID 10945511

Evidence scope. Postmenopausal women; matrix patch; some also received medroxyprogesterone.

Transdermal estradiol avoids first-pass hepatic metabolism.

Physiological levels of estradiol (the major estrogen secreted by the ovaries in premenopausal women) can therefore be maintained in postmenopausal women with low daily doses because first-pass hepatic metabolism is avoided.

Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs · 1990 · PMID 2083514

Evidence scope. Pharmacology review; postmenopausal HRT.

Application-site irritation was the most common adverse effect in transdermal-estradiol trials.

Transdermal estradiol has been well tolerated in clinical trials, with local irritation at the site of application being the most common adverse effect.

Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs · 1990 · PMID 2083514

Evidence scope. Human trial review; dose and event rate absent.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Quantified PK: 3x oral bioavailability and 40-100 pg/mL steady state. The checked abstracts did not support these numbers.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

Thyroid replacementCompatible but estrogen raises TBG - free T4 may drop; monitor TSH after starting.

Testosterone (low-dose female HRT)Commonly paired in female HRT for energy, libido, and body composition benefits.

ProgesteroneRequired adjunct in women with a uterus to prevent endometrial hyperplasia.

Keep separate

Combined hormonal contraceptivesAdditive estrogen exposure raises thrombosis risk - do not stack.

Anastrozole / LetrozoleAromatase inhibitors directly oppose estradiol replacement. Only combined under specialist direction.

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Side effects & safety

Commonly reported

Application site reaction
Breast tenderness
Headache
Nausea
Water retention

Less common & notes

Unscheduled bleeding
Mood changes
Libido changes
Melasma

Pharmacokinetics

Illustrative plasma concentration · 17 h

Half-life

~4 hours

After patch removal

Peak · Tmax

Steady state by day 2-3 of continuous wear

Elimination

Detectable serum levels 24-48 hours after removal

Bioavailability

~100%

Transdermal (bypasses hepatic first pass)

Duration of action

3-4 days

Per patch (twice-weekly cadence)

Clearance

Hepatic CYP3A4 to estrone, then sulfate/glucuronide conjugates. Renal excretion.

Storage. Store pouched patches at controlled room temperature (20-25C / 68-77F). Do not store unpouched. Keep away from direct sunlight and heat sources. Apply immediately upon opening pouch.

Regulatory status

FDA-approved for menopausal symptoms, osteoporosis prevention, and hypogonadism. Prescription-only. Black-box warning on WHI-associated risks (VTE, stroke, breast cancer). Matrix-type patches are NOT cuttable per FDA label.

Put it to work

Calculate, log & track

Open Estradiol Transdermal Patch straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Estradiol Transdermal Patch in the app →

Go deeper

The guide & community

The complete Estradiol Transdermal Patch walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community